Program
Clonidine
Also written as “Ropivacaine + Clonidine + Betamethasone”, “Naltrexone and Clonidine Combination” and “Clonidine Gel 0.1%”.
Its studies are mostly in Low Back Pain · Diabetic Neuropathies · Attention Deficit Disorder with Hyperactivity · Hypertension, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Annette C. Toledano MD | 10 open or running | phase 2since Aug 11, 2011 | Aug 11, 2011 | none ahead |
| BioDelivery Sciences International | 10 open or running | phase 2since Feb 19, 2014 | Feb 19, 2014 | none ahead |
| Concordia Pharmaceuticals Inc., Barbados | 10 open or running | phase 4since Sep 13, 2011 | Sep 13, 2011 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 11, 2011First study: phase 2 study in Back PainNew to Annette C. Toledano MDAnnette C. Toledano MD · NCT01415895 · 78 enrolled · United States
- Sep 13, 2011Concordia Pharmaceuticals Inc., Barbados's first study: phase 4 study in Attention Deficit Disorder with HyperactivityNew to Concordia Pharmaceuticals Inc., BarbadosConcordia Pharmaceuticals Inc., Barbados · NCT01439126 · 135 enrolled
- Feb 19, 2014BioDelivery Sciences International's first study: phase 2 study in Diabetic NeuropathiesNew to BioDelivery Sciences InternationalBioDelivery Sciences International · NCT02068027 · 260 enrolled · United States
TargetBeta
“Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| brimonidinerule | AbbVie | phase 4 | 54 |
| Dexmedetomidinerule | Pfizer | phase 4 | 46 |
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| tizanidinerule | Teva Pharmaceutical Industries | phase 4 | 11 |
| lofexidinerule | uswm-llc-dba-us-worldmeds | phase 3 | 15 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT02068027Diabetic Neuropathies · United States | 2 | Completed | BioDelivery Sciences International | Mar 2015 | 260 |
| NCT01439126Attention Deficit Disorder with Hyperactivity | 4 | Completed | Concordia Pharmaceuticals Inc., Barbados | Oct 2012 | 135 |
| NCT01415895Back Pain · United States | 2 | Completed | Annette C. Toledano MD | Feb 2013 | 78 |
How it is read
Names in the registry
- “Ropivacaine + Clonidine + Betamethasone”, 3 entries
- “Naltrexone and Clonidine Combination”, 1 entry
- “Clonidine Gel 0.1%”, 1 entry
- “clonidine hydrochloride”, 1 entry
- “Clonidine”, 1 entry
Conditions, from the studies’ own filings
- Low Back Pain, 1 study
- Diabetic Neuropathies, 1 study
- Attention Deficit Disorder with Hyperactivity, 1 study
- Hypertension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.